Department of Gastroenterology, First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China.
Gastroenterology Institute of Jiangxi Province, Nanchang, Jiangxi, China.
Front Public Health. 2023 Jan 30;11:1039782. doi: 10.3389/fpubh.2023.1039782. eCollection 2023.
Patients with inflammatory bowel disease (IBD) often require immunosuppressive therapy and are hence susceptible to various opportunistic viral and bacterial infections. In this regard, many studies on IBD and COVID-19 have been conducted. However, no bibliometric analysis has been performed. This study provides a general overview of IBD and COVID-19.
Publications about IBD and COVID-19 from 2020 to 2022 were retrieved from the Web of Science Core Collection (WoSCC) database. Bibliometric analysis was performed using VOSviewer, CiteSpace, and HistCite.
A total of 396 publications were retrieved and considered in this study. The maximum number of publications were from the United States, Italy, and England, and the contributions of these countries were significant. Kappelman ranked first in article citations. The Icahn School of Medicine at Mount Sinai and were the most prolific affiliation and journal, respectively. The most influential research topics were "management", "impact", "vaccination", and "receptor". The following keywords represented research frontiers: "depression", "the quality of life of IBD patients", "infliximab", "COVID-19 vaccine", and "second vaccination".
Over the past 3 years, most studies on IBD and COVID-19 have focused on clinical research. In particular, topics such as "depression", "the quality of life of IBD patients", "infliximab", "COVID-19 vaccine", and "second vaccination" were noted to have received much attention recently. Future research should focus on our understanding of the immune response to COVID-19 vaccination in biologically treated patients, the psychological impact of COVID-19, IBD management guidelines, and the long-term impact of COVID-19 in IBD patients. This study will provide researchers with a better understanding of research trends on IBD during COVID-19.
炎症性肠病（IBD）患者常需接受免疫抑制治疗，因此易发生各种机会性病毒和细菌感染。在此方面，已有许多关于 IBD 和 COVID-19 的研究，但尚无文献计量分析。本研究对 IBD 和 COVID-19 进行了综述。
从 Web of Science 核心合集（WoSCC）数据库中检索 2020 年至 2022 年发表的关于 IBD 和 COVID-19 的文献，采用 VOSviewer、CiteSpace 和 HistCite 进行文献计量分析。
共检索到 396 篇文献并纳入本研究。发文量最多的国家是美国、意大利和英国，这些国家的贡献显著。Kappelman 的文章被引频次最高。发文量最多的机构是西奈山伊坎医学院，发文量最多的期刊是《炎症性肠病杂志》。最有影响力的研究主题是“管理”“影响”“疫苗接种”和“受体”。代表研究前沿的关键词有“抑郁”“IBD 患者的生活质量”“英夫利昔单抗”“COVID-19 疫苗”和“二次接种”。
过去 3 年，IBD 和 COVID-19 的研究多集中在临床研究方面，尤其关注“抑郁”“IBD 患者的生活质量”“英夫利昔单抗”“COVID-19 疫苗”和“二次接种”等主题。未来研究应聚焦于深入了解生物治疗患者对 COVID-19 疫苗的免疫反应、COVID-19 的心理影响、IBD 管理指南以及 COVID-19 对 IBD 患者的长期影响。本研究可为研究者提供 COVID-19 期间 IBD 研究趋势的更好理解。
